
Cat. #162307
IDHmut glioma stem-like NCH3763 cell line
Cat. #: 162307
Organism: Human
Tissue: Brain
£575.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Christel Herold-Mende
Institute: Heidelberg University
Primary Citation: Trong et al. 2023. Cells. 12(8):1200. PMID: 37190109.
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Name: IDHmut glioma stem-like NCH3763 cell line
- Cancer type: Brain cancer
- Organism: Human
- Tissue: Brain
- Growth properties: Mixed - adherent and suspension
- Description: Glioma stem-like cell line NCH3763 expressing mutant isocitrate dehydrogenase (IDH), used to model low-grade gliomas or secondary glioblastomas
- Biosafety level: 2
Handling
- Growth medium: DMEM/Ham F-12 supplemented with 1% Penicillin/Streptomcyin, 1% 200mM Glutamine (preferably Glutamax), 10% BIT supplement (PeloBiotech), bFGF and EGF
- Temperature: 37°C
- Atmosphere: 5% CO2
- Storage conditions: FCS-free freezing medium (Synth-a-freeze medium)
References
- Trong et al. 2023. Cells.12(8):1200. PMID: 37190109.
- Trong et al. 2020. Cells. 9(6):1389. PMID: 32503220.
![Anti-CAR Whitlow Linker [1C3C3]](https://cancertools.org/wp-content/uploads/Figure-6-Kimble-et-al.-J-Immunother-Cancer-2025-300x322.jpg 300w, https://cancertools.org/wp-content/uploads/Figure-6-Kimble-et-al.-J-Immunother-Cancer-2025-280x300.jpg 280w, https://cancertools.org/wp-content/uploads/Figure-6-Kimble-et-al.-J-Immunother-Cancer-2025-954x1024.jpg 954w, https://cancertools.org/wp-content/uploads/Figure-6-Kimble-et-al.-J-Immunother-Cancer-2025-768x824.jpg 768w, https://cancertools.org/wp-content/uploads/Figure-6-Kimble-et-al.-J-Immunother-Cancer-2025.jpg 1193w)

![Anti-CAR Whitlow Linker [1B4A1]](https://cancertools.org/wp-content/uploads/Figure-5-Kimble-et-al.-J-Immunother-Cancer-2025-300x396.jpg 300w, https://cancertools.org/wp-content/uploads/Figure-5-Kimble-et-al.-J-Immunother-Cancer-2025-227x300.jpg 227w, https://cancertools.org/wp-content/uploads/Figure-5-Kimble-et-al.-J-Immunother-Cancer-2025-776x1024.jpg 776w, https://cancertools.org/wp-content/uploads/Figure-5-Kimble-et-al.-J-Immunother-Cancer-2025-768x1013.jpg 768w, https://cancertools.org/wp-content/uploads/Figure-5-Kimble-et-al.-J-Immunother-Cancer-2025.jpg 970w)


